TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis C$1.55 +0.06 (+4.03%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades About Oncolytics Biotech Stock (TSE:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncolytics Biotech alerts:Sign Up Key Stats Today's RangeC$1.45▼C$1.6050-Day RangeC$1.18▼C$1.9152-Week RangeC$1.15▼C$2.32Volume94,739 shsAverage Volume70,787 shsMarket CapitalizationC$119.13 millionP/E RatioN/ADividend Yield0.31%Price TargetC$3.50Consensus RatingBuy Company OverviewOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Oncolytics Biotech Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreONC MarketRank™: Oncolytics Biotech scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has received no research coverage in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 6.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth.Read more about Oncolytics Biotech's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media2.4 / 5News Sentiment0.28 News SentimentOncolytics Biotech has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.Search Interest5 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.82% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 1.75% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesOncolytics Biotech Announces Q3 Results ConferenceNovember 11 at 3:16 PM | markets.businessinsider.comEarnings Preview: Oncolytics BiotechNovember 11 at 3:16 PM | benzinga.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 13, 2024 | Crypto Swap Profits (Ad)10 cheap healthcare stocks to buy nowNovember 11 at 5:12 AM | msn.comOncolytics targets accelerated approval for oncolytic virus therapyOctober 18, 2024 | msn.comFDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%October 4, 2024 | baystreet.caBuzz on the Bullboards: TSX stocks making headlines this weekSeptember 26, 2024 | msn.comTransgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025September 24, 2024 | finance.yahoo.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncolytics Biotech's stock was trading at C$1.79 at the beginning of 2024. Since then, ONC stock has decreased by 13.4% and is now trading at C$1.55. View the best growth stocks for 2024 here. How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Barrick Gold (GOLD). Company Calendar Today11/12/2024Next Earnings (Confirmed)11/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ONC CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.50 High Stock Price TargetC$3.50 Low Stock Price TargetC$3.50 Potential Upside/Downside+125.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-138.22% Return on Assets-71.33% Debt Debt-to-Equity Ratio6.09 Current Ratio4.99 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.37 per share Price / Cash Flow4.22 Book ValueC$0.24 per share Price / Book6.46Miscellaneous Outstanding Shares76,860,000Free FloatN/AMarket CapC$119.13 million OptionableNot Optionable Beta1.35 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (TSE:ONC) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.